![](/img/cover-not-exists.png)
Comparison between IFNalpha2a + ribavirin and IFNalpha2a + amantadine combination therapy in naive patients with chronic hepatitis C-genotype 1, and between amantadine and ribavirin addition in non responders after 3 months
Antonio Bellobuono, R. Finazzi, G. Covini, L. Milazzo, C. Magni, A.M. Milella, C. Janoletti, F. Bozzetti, Andrea Bellobuono, G. IdéoVolume:
36
Year:
2002
Language:
english
DOI:
10.1016/s0168-8278(02)80345-2
File:
PDF, 108 KB
english, 2002